摘要
目的分析耐多药肺结核标准化治疗过程中不良反应的发生情况,并评价其对治疗的影响。方法在全国选取4个地市,采用统一设计的不良反应调查问卷,回顾性调查129例耐多药肺结核患者病案。结果 48.1%的患者发生1种以上不良反应,发生不良反应的患者中,80.6%的患者通过调整剂量或者药物种类能够继续治疗,仅有19.4%的患者因为不良反应终止耐多药肺结核治疗;最常见的不良反应为胃肠反应,发生率为26.4%,其次是肝脏毒性反应,发生率为15.5%。结论尽管耐多药肺结核治疗过程中容易发生不良反应,但是通过定期监测、早期发现和合理处理不良反应,大部分患者能够继续治疗。
Objective To analyze the adverse drug reactions （ADR） of the standardized treatment of muhidrug re- sistant tuberculosis（ MDR-TB）, and to evaluate the impact on treatment. Methods Four provinces were selected as re- search sites and the retrospective study was used to investigate 129 MDR-TB medical records in four project prefectures u- sing standard ADR questionnaire. Results 48. 1% cases had more than one ADR during the treatment, 80. 6% cases continued the treatment by adjusting the drug doses or changing drugs, only 19. 4% cases stopped MDR-TB treatment for ADR. The most common ADR was gastrointestinal reaction, which accounted for 26.4%. Secondly came hepatotoxicity, which accounted for 15.5%. Conclusions Although ADR is common during the treatment of MDR-TB, through routine monitoring, timely detection and appropriate treatment of ADR, patients can be guaranteed the continuous therapy.
出处
《中华疾病控制杂志》
CAS
北大核心
2013年第3期243-245,共3页
Chinese Journal of Disease Control & Prevention
基金
中国卫生部-盖茨基金会结核病防治项目(51914)
关键词
结核
肺
广泛耐药结核
治疗
Tuberculosis, pulmonary
Extensively drug-resistant tuberculosis
Therapy
